Dmitrewski J, El-Gazzaz G, McMaster P
The Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK.
J Hepatobiliary Pancreat Surg. 1998;5(1):18-23. doi: 10.1007/pl00009945.
Surgery remains the treatment of choice for hepatocellular carcinoma (HCC). For HCC without underlying cirrhosis resection remains the mainstay treatment option. Prognosis depends on the stage of the tumor. Survival appears to be better for small (less than 5 cm) solitary tumors with negative resection margins and absence of vascular invasion. At present, liver transplantation does not have an established role in the treatment of HCC in a non-cirrhotic liver. Because of the high recurrence rate, it should not be considered for more advanced disease which is not amenable to resection. The surgical approach in cirrhotics depends not only on the stage of the tumor but also on the liver functional reserve. Tumor size, presence of multifocal disease, and vascular invasion determine the risk of HCC recurrence after resection, and the functional stability of the liver determines both resectability and outcome. In societies in which transplantation is not available, small tumors will be treated with liver resection. The outcome in patients with well preserved liver function is relatively good, at least in the medium term. However, recurrent tumor and progressive hepatic decompensation have significant adverse effects on long-term survival. Poor functional reserve may be associated with significant perioperative mortality and lower survival due to progressive liver failure. In our opinion, for small cirrhosis-related HCCs, liver transplantation offers better long-term prospects than resection. Therefore, if liver transplantation is available as an option it should be considered as the treatment of choice, particularly for younger patients with otherwise good life expectancy.
手术仍然是肝细胞癌(HCC)的首选治疗方法。对于没有潜在肝硬化的HCC,切除仍然是主要的治疗选择。预后取决于肿瘤的分期。对于小的(小于5厘米)、切缘阴性且无血管侵犯的孤立肿瘤,生存率似乎更好。目前,肝移植在非肝硬化肝脏的HCC治疗中尚未确立其作用。由于复发率高,对于无法切除的更晚期疾病不应考虑肝移植。肝硬化患者的手术方法不仅取决于肿瘤分期,还取决于肝脏功能储备。肿瘤大小、多灶性疾病的存在以及血管侵犯决定了切除后HCC复发的风险,而肝脏的功能稳定性则决定了可切除性和预后。在无法进行移植的地区,小肿瘤将采用肝切除术治疗。肝功能良好的患者预后相对较好,至少在中期是这样。然而,肿瘤复发和进行性肝失代偿对长期生存有显著的不利影响。功能储备差可能与围手术期死亡率显著增加以及因进行性肝衰竭导致的生存率降低有关。我们认为,对于与肝硬化相关的小HCC,肝移植比切除术提供了更好的长期前景。因此,如果有肝移植作为选择,则应将其视为首选治疗方法,特别是对于预期寿命较长的年轻患者。